CRISPR, μια νέα τεχνολογία γενετικής παρέμβασης: Πρόταση αξιοποίησης σε ένα δημόσιο σύστημα υγείας

PDF (ελληνικά) PDF (English)
Veröffentlicht: Σεπ 25, 2020
DOI: https://doi.org/10.12681/bioeth.24843
Nikolaos Kolisis (Νικόλαος Κολίσης)
MPhil, Postgraduate Student in Philosophy of Law, University of Athens, Athens.
Abstract

Οι νέες τεχνολογίες γενετικής παρέμβασης στο ανθρώπινο γονιδίωμα μέσω της χρήσης του συστήματος των Clustered Regularly Interspaced Short Palindromic Repeats και των σχετιζόμενων νουκλεασών (CRISPR) έχουν γίνει αντικείμενο προβληματισμού μεταξύ βιο-επιστημόνων, φιλοσόφων και νομικών. Το παρόν κείμενο, αφού λάβει υπ’ όψιν την υπάρχουσα συζήτηση σχετικά με τα βιοηθικά ζητήματα που αναδεικνύονται από τις εφαρμογές του CRISPR στον άνθρωπο, διατυπώνει ένα προβληματισμό σχετικά με το πώς θεραπείες που βασίζονται σε αυτό το καινοτόμο εργαλείο επεξεργασίας γονιδίων θα μπορούσαν να αξιοποιηθούν από ένα δημόσιο σύστημα υγείας. Για το σκοπό αυτό προτείνει μια μέθοδο ακριβοδίκαιης και βιώσιμης ένταξης αυτών των νέων θεραπειών στο σύστημα παροχών ενός δημόσιου συστήματος υγείας.

Article Details
  • Rubrik
  • Original Articles
Creative-Commons-Lizenz
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung 4.0 International.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution  CC BY 4.0 License, which allows for immediate free access to the work and permits any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose. Appropriate credit must be given by citing the author(s) and the original publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

We encourage authors to deposit their articles, as well as data underlying the publications, in institutional and/or other appropriate subject repositories.

Bioethica permits and encourages authors to archive the final publication pdf  in institutional (e.g. the repository of the National Hellenic Research Foundation) or other appropriate subject repositories (e.g. SSOAR repository for social sciences),  in compliance with institutional and/or funder open access policies, after publication in the BIOETHICA. Authors must provide bibliographic details that credit publication in the journal, as well as related funding details (when applicable).

Lists of institutional and other subject-based academic open access repositories can be found listed by country at the registry http://opendoar.org/countrylist.php   

If your institution does not possess a repository you may deposit a copy of your paper at no cost with www.zenodo.org , the repository supported for open access research in the EU by the European Commission, through the project OpenAIRE (www.openaire.eu )

Downloads
Keine Nutzungsdaten vorhanden.
Literaturhinweise
Atlan, H. La fin du tout génétique: Vers de nouveaux paradigmes en biologie: Editions Quæ, Versailles, France, 1999.
Baylis F. Altered Inheritance: CRISPR and the Ethics of Human Genome Editing, Harvard University Press 2019.
Buchanan, A. Human Nature and Enhancement. 2009 Bioethics 23: 141-50.
Cwik B. Moving Beyond 'Therapy' and 'Enhancement' in the Ethics of Gene Editing. Camb Q Health Ethics, 2019 28: 695-707.
D’Amato, A. Do we owe a Duty to Future Generations to Preserve the Global Environment? American Journal of International Law, 84(1) 1990, 190-198.
Davies K. Walk the Line: Debating a Germline Editing Moratorium. The CRISPR Journal, 2 2019: 74-76.
Gyngell, C. and Douglas, T. Selecting Against Disability: The Liberal Eugenic Challenge and the Argument from Cognitive Diversity. J Appl Philos, 2018, 35: 319-340.
Kass L.R. Making Babies-the New Biology and the Old Morality. Public Interest, 1972 26: 18-56
Lanphier E., Urnov F., Haecker S.E., et al. Don’t edit the human germ line. Nature, 2015, 519:410-411.
Liang P., Xu Y., Zhang X., et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell, 2015,6: 363-372.
National Academies of Sciences, Engineering, Medicine. Human Genome Editing: Science, Ethics, and Governance. Washington, DC: National Academies Press.
National Academies of Sciences, Engineering. 2019. Second International Summit on Human Genome Editing: Continuing the Global Discussion: Proceedings of a Workshop In Brief: National Academies Press Washington, DC, 2017.
Nestor M.W., Wilson R.L. Can the Use of CRISPR in Humans Result in Decreased Social Justice for Future Stakeholders?” Ethics BiolEng Med 2018, 9: 5-16.
Parens E. Should We Hold the (Germ) Line? J Law Med Ethics, 1995, 23: 173-76.
Parfit, D. Future People, the Non‐Identity Problem, and Person‐Affecting Principles. Philosophy & Public Affairs, 2017, 45: 118-157.
Scanlon, Τ.Μ. WhyDoes Inequality Matter? Oxford University Press, 2018.
The Nuffield Council on Bioethics. Genome editing and human reproduction: social and ethical issues. 2018. https://www.nuffieldbioethics.org/publications/genome-editing-and-human-reproduction.
Ünal M., Unal D. Gene Doping in Sports. Sports medicine Auckland, N.Z., 2004 34: 357-62.
Van Dijke I., Bosch L., Bredenoord A., et al. The ethics of clinical applications of germline genome modification: a systematic review of reasons. Hum Reprod, 2018, 33: 1777-1796.
Wilson RC, Carroll D. The Daunting Economics of Therapeutic Genome Editing. The CRISPR Journal, 2019, 2:280-284.
Ευρωπαϊκή Σύμβαση για τη Βιοϊατρική (Σύμβαση Οβιέδο) (σχετικά με παρεμβάσεις σε έμβρυα και γενικά στο ανθρώπινο γονιδίωμα, ιδίως άρθρα 5, 6, 10, 18, 21, 22).